Introduction
Alzheimer's disease is a neurodegenerative disorder primarily affecting older adults, characterized by progressive cognitive decline and behavioral changes. The APOE genetic marker (Apolipoprotein E) is a key gene responsible for assessing an individual’s risk of developing Alzheimer’s disease. Our Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing) can provide you with results that will guide you in making appropriate lifestyle changes.
What clinical challenges are targeted by Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing)
APOE is a significant genetic risk factor for Alzheimer's disease. The APOE4 allele greatly increases the risk of developing Alzheimer's disease, with individuals carrying two APOE4 alleles facing up to a 15-fold higher risk. In contrast, the APOE2 allele can reduce the risk by nearly half and may also help extend lifespan[1].
The Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing) uses MALDI-TOF MS technology to analyze two APOE gene loci, rs429358 and rs7412, aiding clinicians in evaluating the likelihood and progression of the Alzheimer's disease.
Applicable Scenarios
- Individuals with cognitive impairment who need risk stratification.
- Individuals suspected of having Alzheimer's disease and related cognitive disorders.
- High-risk individuals with a family history of Alzheimer's disease.
- Individuals concerned about neurocognitive diseases and brain health.
Important features of Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing)
| Product Name | Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing) |
| Detection Method | MALDI-TOF MS technology |
| Detection Scope | The six genotypes (ɛ2/ɛ2, ɛ2/ɛ3, ɛ3/ɛ3, ɛ2/ɛ4, ɛ3/ɛ4, and ɛ4/ɛ4) formed by two functional SNP sites of the APOE gene, rs429358 and rs7412. |
| Sample Type | Peripheral Blood; Oral Swab; Genomic DNA; Dried Blood Spot |
Why Choose Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing)
- High Specificity
The MALDI-TOF MS technology detects low-abundance biomolecules through unique peaks and fingerprint features in mass spectrometry spectra. - Simple and Fast
Requires only a single reaction to produce easy and reliable results. Turnaround time is 10 working days. - Variety of Samples
Peripheral blood, oral swabs, genomic DNA, and dried blood spots can all be tested.
The Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing)
Step 1
Physician orders test
Step 2
Sample collected
Step 3
Sample shipped to us and analyzed
Step 4
Results sent to physician
Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing) Resources
Learn more about our product solution by downloading our relevant materials.
Alzheimer's Disease Risk Genetic Testing (APOE Genotyping Testing)